Please login to the form below

Not currently logged in
Email:
Password:

Celgene settles with Elan over cancer drug

Celgene has agreed to pay $76m to settle patent infringement litigation filed by Elan involving the breast cancer drug Abraxane

Celgene has agreed to pay $76m to settle patent infringement litigation filed by Elan involving the breast cancer drug Abraxane, a modified form of paclitaxel that Celgene acquired through its October 2010 merger with the biotech company Abraxis BioScience.

Abraxane won US approval in early 2005 as a treatment for breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. The drug was approved in Europe for a similar indication in 2008.

The settlement and licence agreement resolves Elan's 2006 suit against Abraxis through the one-time payment. Elan is not entitled to any additional payments tied to sales of Abraxane or any other products that make use of Abraxis' nab-Paclitaxel technology, which wraps paclitaxel inside albumin, a naturally-occurring human protein, allowing the drug to be administered to the tumour site at higher doses than previously possible. Abraxis is investigating the technology for use in other indications, including non-small cell lung cancer, pancreatic cancer and melanoma.

Celgene will acquire a fully-paid up, exclusive, worldwide licence to select Elan US and foreign patents for Abraxane.

In June 2008, a jury awarded Elan $55.2m in damages in federal court in Wilmington, Delaware, after it determined that Abraxis had infringed a patent covering the coated nanoparticles used in Abraxane. Abraxis appealed the decision, eventually leading to the current settlement.

Celgene bought Abraxis last year for around $2.9bn in upfront payments, in addition to potential milestone payments and royalties due to shareholders.

25th February 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
#DemandDiversity: Black history in clinical trials: It's more than just Tuskegee [Infographic]
Take a look at this infographic showing some of the most notorious clinical trials and medical research in history....
Looking back at the year when everything changed
COVID-19 has impacted every aspect of our lives, from the way we shop for groceries to the way we conduct work and interact with healthcare providers and our families....

Infographics